Baird analyst Jack Allen lowered the firm’s price target on MiNK Therapeutics (INKT) to $4 from $8 and keeps an Outperform rating on the shares. The firm said the company announced 3Q24 financials and provided pipeline updates, which were generally in line with expectations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT: